Hostname: page-component-76d6cb85b7-5qg8f Total loading time: 0 Render date: 2026-07-13T00:22:45.013Z Has data issue: false hasContentIssue false
  • English
  • Français

Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures

Published online by Cambridge University Press:  01 January 2021

Ariel Dora Stern
Get access Rights & Permissions [Opens in a new window]

Abstract

The use of biomarkers holds great promise for the development of new therapeutics and the acceleration of clinical research. However, biomarkers must be validated — a complex and costly endeavor. Importantly, biomarker validation is meaningfully shaped by economic and policy-driven incentives.

Information

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 47 , Issue 3: Biomarker Research and Validation: Current Challenges, Future Opportunities , Fall 2019 , pp. 396 - 397
Copyright
Copyright © American Society of Law, Medicine and Ethics 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Hey, S. P. et al., “Challenges and Opportunities for Biomarker Validation,” Journal of Law, Medicine & Ethics 47, no. 3 (2019): 357-361.CrossRefGoogle Scholar
Li, R. and Sim, I., “How Clinical Trial Data Sharing Platforms Can Advance the Study of Biomarkers,” Journal of Law, Medicine & Ethics 47, no. 3 (2019): 369-373; Shrager, J. et al., “Is Cancer Solvable? Towards Efficient and Ethical Biomedical Science,” Journal of Law, Medicine & Ethics 47, no. 3 (2019): 362-368.CrossRefGoogle Scholar
Mavergames, C. et al., “Cochrane's Linked Data Project: How It can Advance Our Understanding of Surrogate Endpoints,” Journal of Law, Medicine & Ethics 47, no. 3 (2019): 374-380; Hey, S. P. et al., “Surrogate Endpoints and Drug Regulation: What is Needed to Clarify the Evidence,” Journal of Law, Medicine & Ethics 47, no. 3 (2019): 381-387.CrossRefGoogle Scholar
Stern, A. D., Alexander, B. M., and Chandra, A., “Innovation Incentives and Biomarkers,” Clinical Pharmacology & Therapeutics 103, no. 1 (2018): 34-36.CrossRefGoogle Scholar
Stern, A. D., Alexander, B. M., and Chandra, A., “How Economics can Shape Precision Medicines,” Science 355, no. 6330 (2017): 1131-1133.CrossRefGoogle Scholar
Taichman, D. B., Sahni, P., Pinborg, A., Peiperl, L., Laine, C., James, A., Hong, S. T., Haileamlak, A., Gollogly, L., Godlee, F., and Frizelle, F. A., “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors,” JAMA 317, no. 24 (2017): 2491-2492; Califf, R. M., Zarin, D. A., Kramer, J. M., Sherman, R. E., Aberle, L. H., and Tasneem, A., “Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010,” JAMA 307, no. 17 (2012): 1838-1847.CrossRefGoogle Scholar